Avorn J - Search Results

1

Projected spending for brand-name drugs in English primary care given US prices: a cross-sectional study.

Liu M, MacKenna B, Feldman WB, Walker AJ, Avorn J, Kesselheim AS, Goldacre B. Liu M, et al. Among authors: avorn j. J R Soc Med. 2020 Sep;113(9):350-359. doi: 10.1177/0141076820918238. J R Soc Med. 2020. PMID: 32910868 Free PMC article.

2

University-based science and biotechnology products: defining the boundaries of intellectual property.

Kesselheim AS, Avorn J. Kesselheim AS, et al. Among authors: avorn j. JAMA. 2005 Feb 16;293(7):850-4. doi: 10.1001/jama.293.7.850. JAMA. 2005. PMID: 15713775

3

Biomedical patents and the public's health: is there a role for eminent domain?

Kesselheim AS, Avorn J. Kesselheim AS, et al. Among authors: avorn j. JAMA. 2006 Jan 25;295(4):434-7. doi: 10.1001/jama.295.4.434. JAMA. 2006. PMID: 16434634 No abstract available.

4

The rise and fall of Natrecor for congestive heart failure: implications for drug policy.

Kesselheim AS, Fischer MA, Avorn J. Kesselheim AS, et al. Among authors: avorn j. Health Aff (Millwood). 2006 Jul-Aug;25(4):1095-102. doi: 10.1377/hlthaff.25.4.1095. Health Aff (Millwood). 2006. PMID: 16835191

5

Extensions of intellectual property rights and delayed adoption of generic drugs: effects on medicaid spending.

Kesselheim AS, Fischer MA, Avorn J. Kesselheim AS, et al. Among authors: avorn j. Health Aff (Millwood). 2006 Nov-Dec;25(6):1637-47. doi: 10.1377/hlthaff.25.6.1637. Health Aff (Millwood). 2006. PMID: 17102189

6

The role of litigation in defining drug risks.

Kesselheim AS, Avorn J. Kesselheim AS, et al. Among authors: avorn j. JAMA. 2007 Jan 17;297(3):308-11. doi: 10.1001/jama.297.3.308. JAMA. 2007. PMID: 17227983 No abstract available.

7

The variability and quality of medication container labels.

Shrank WH, Agnew-Blais J, Choudhry NK, Wolf MS, Kesselheim AS, Avorn J, Shekelle P. Shrank WH, et al. Among authors: avorn j. Arch Intern Med. 2007 Sep 10;167(16):1760-5. doi: 10.1001/archinte.167.16.1760. Arch Intern Med. 2007. PMID: 17846395

8

Pharmaceutical promotion to physicians and First Amendment rights.

Kesselheim AS, Avorn J. Kesselheim AS, et al. Among authors: avorn j. N Engl J Med. 2008 Apr 17;358(16):1727-32. doi: 10.1056/NEJMsb0708920. N Engl J Med. 2008. PMID: 18420505 No abstract available.

9

Using patent data to assess the value of pharmaceutical innovation.

Kesselheim AS, Avorn J. Kesselheim AS, et al. Among authors: avorn j. J Law Med Ethics. 2009 Summer;37(2):176-83. doi: 10.1111/j.1748-720X.2009.00364.x. J Law Med Ethics. 2009. PMID: 19493065

10

Balancing innovation, access, and profits--market exclusivity for biologics.

Engelberg AB, Kesselheim AS, Avorn J. Engelberg AB, et al. Among authors: avorn j. N Engl J Med. 2009 Nov 12;361(20):1917-9. doi: 10.1056/NEJMp0908496. Epub 2009 Oct 14. N Engl J Med. 2009. PMID: 19828525 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

613 results

Search Page

Filters